Management of locoregional stage esophageal cancer: a single center experience.


Journal Article

Therapeutic options for locoregional esophageal cancer (EC) include primary surgery, neoadjuvant or definitive chemoradiation and systemic chemotherapy. The role of surgery in these multimodal strategies has recently been debated and definitive chemoradiation is being offered as an alternative to surgery at many centers. We examined our results with multimodal therapy and surgery in this patient population. We conducted a retrospective analysis of 172 patients with locoregional (AJCC stages I-III) EC treated at RPCI between February 14, 1990 and September 20, 2002. Median age was 65 years (range, 36-95); there were 136 male patients. There were 100 regional (stages IIB-III), 69 local (stages I-IIA) and three in situ cases. Initial therapy was either combined modality (n = 122) or single modality (surgery) (n = 50). There was 0%, 30-day, postoperative mortality. Median survival for all patients was 25.3 months and was better for local stage with surgery alone (75 months) than with neoadjuvant (35.7 months) or definitive chemoradiation (19.1 months, P < 0.001). Survival for patients with regional disease treated with surgery alone, neoadjuvant or definitive chemoradiation was 21.5, 24.4 and 11.8 months, respectively (P = not significant). The associations of prognostic factors with overall survival were evaluated using Cox proportional hazards regression analysis and 2-sided Wald's chi-square test. On multivariate analysis, carefully selected patients treated with surgery alone had better outcomes compared with those treated with definitive chemoradiation (P < 0.001). Patients with locoregional esophageal cancer who are eligible for surgical resection either alone or as a part of multimodal therapy may have better outcomes than those treated with non-surgical approaches.

Full Text

Cited Authors

  • Javle, MM; Nwogu, CE; Donohue, KA; Iyer, RV; Brady, WE; Khemka, SV; Smith, JL; Demmy, TL; Yang, GY; Nava, HR

Published Date

  • January 2006

Published In

Volume / Issue

  • 19 / 2

Start / End Page

  • 78 - 83

PubMed ID

  • 16643174

Pubmed Central ID

  • 16643174

Electronic International Standard Serial Number (EISSN)

  • 1442-2050

International Standard Serial Number (ISSN)

  • 1120-8694

Digital Object Identifier (DOI)

  • 10.1111/j.1442-2050.2006.00544.x


  • eng